Russian Journal of OncologyRussian Journal of OncologyРоссийский онкологический журнал1028-99842412-9119Eco-Vector3999810.17816/onco39998ArticlesСтатьиReview ArticleRADIATION DETECTION OF BREAST CANCER IN WOMEN WITH A GENETIC PREDISPOSITION OR FAMILY HISTORY (REVIEW)ЛУЧЕВАЯ ДИАГНОСТИКА РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ У ЖЕНЩИН С ГЕНЕТИЧЕСКОЙ ПРЕДРАСПОЛОЖЕННОСТЬЮ И ОТЯГОЩЕННЫМ СЕМЕЙНЫМ АНАМНЕЗОМKarpovaM. SКарповаМарина Сергеевна

аспирант рентгенодиагностического отд-ния отд. лучевой диагностики и рентгенохирургических методов лечения

mskarpova@bk.ruKorzhenkovaG. PКорженковаГалина Петровна

к. м. н., старший научный сотрудник, рентгенодиагностическое отделение отдела лучевой диагностики и рентгенохирургических методов лечения

gkorzhenkova@mail.ruLubchencoL. NЛюбченкоЛюдмила Николаевна

д.м.н, заведующая лабораторией клинической онкогенетики

clingen@mail.ruDolgushinB. IДолгушинБорис Иванович

член-корреспондент РАМН, д. м. н., профессор, заведующий рентгенодиагностического отделения отдела лучевой диагностики и рентгенохирургических методов лечения

N.N.Blokhin Russian Cancer Research Center of the Russian Academy of Medical SciencesФГБУ "Российский онкологический научный центр им. Н.Н. Блохина" РАМН15042013182NO2 (2013)№2 (2013)465422072020Copyright ©; 2013, Eco-VectorCopyright ©; 2013, ООО "Эко-Вектор"2013Eco-VectorООО "Эко-Вектор"https://rjonco.com/1028-9984/article/view/39998

Screening of breast cancer with mammography recommended to women below the age of 40 years old has been shown to decrease mortality from breast cancer. But there is group of young women with high risk for developing breast cancer. The main part of this group are women with BRCA 1/2 mutations and women with strong family histories without known BRCA 1/2 mutations. Mammography has much lower accuracy in women under 40 years especially genetic mutation carriers compared to sporadic cases of breast cancer. For this reason there is necessity in new screening methods of young high-risk women to detect early-stage cancers.

Маммографический скрининг, рекомендованный женщинам старше 40 лет, снижает смертность от рака молочной железы (РМЖ). Но существует группа молодых женщин высокого риска развития рака молочной железы, для которых значение маммографии(МГ) остается под вопросом. Основную часть этой группы составляют женщины с отягощенным семейным анамнезом (семейный рак) и носители мутаций BRCA(Breast Cancer Associated) 1 и BRCA2-генов и др. МГ оказалась малоэффективной в группе молодых женщин, особенно носительниц генетических мутаций. В связи с этим встал вопрос о введении в скрининговую программу молодых женщин высокого риска дополнительных методов, которые позволили бы выявлять РМЖ в доклинической стадии.

BRCA1BRCA2Breast cancerMagnetic resonance imaging (MRI)MammographyBRCA1BRCA2рак молочной железымагнитно-резонансная томографиямаммографияскринингDavydov M.I., Aksel’ E.M. Incidence of malignant new growths of the population of Russia and CIS countries in 2008. Journal of N. N. Blokhin Russian Cancer Research Center RAMS. 2011; 22[3 (85)]:54-95 (in Russian). Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2008 г. Вестник РОНЦ им. Н. Н. Блохина РАМН. 2011; 22 [3 (85), прил. 1].54-95.Hajlenko V.A. Breast cancer diagnostics.M.: OOO "MIA", 2005; 240 (in Russian). Хайленко В.А. Диагностика рака молочной железы. М.: ООО "МИА"; 2005.Komarova L.E. Mammographic screening and its role in reducing breast cancer mortality. J. Mammology. 2006; 3: 5-10 (in Russian). Комарова Л.Е. Маммографический скрининг и его роль в снижении смертности от рака молочной железы. Маммология. 2006; 3: 5-10.Costanza S.S., Evans W.P., Foster R.S., Hendrick E., Eyre H.J., Smith R.A. et al. American Cancer Society guidelines for breast cancer screening. CA. Cancer J. Clin. 2003; 53 (3): 141-69.Joensuu H., Lehtimaki T., Holli K., Elomaa L., Turpeenniemi-Hujanen T., Kataja V.A. et al. Risk of distant recurrence of breast cancer detected by mammography screening or other methods. J. A. M. A. 2004; 292 (9): 1064-73.Armstrong K., Eisen A., Weber B. Assessing the risk of breast cancer. N. Engl. J. Med. 2000; 342: 564-71.Korzhenkova G.P., Luk’janchenko A.B., Zernov D.I. Capacities of magnetic resonance imaging in the algorithm of examination of patients with breast diseases. J. Mammology. 2006; 1: 39-45 (in Russian). Корженкова Г.П., Лукьянченко А.Б., Зернов Д.И. Возможности магнитно-резонансной томографии в алгоритме обследования пациентов с заболеваниями молочной же лезы. Маммология. 2006; 1: 39-45.Dubsky P.C., Gnant M.F., Taucher S., Roka S., Kandioler D., Pichler-Gebhard B. et al. Clin. Breast Cancer. 2002; 3 (1): 65-72.Anders C.K., Johnson R., Litton J., Phillips M., Bleyer A. Breast cancer before age 40 years. Semin. Oncol. 2009. 36: 237-49.Nixon A.J., Neuberg D., Hayes D.F., Gelman R., Connolly J.L., Schnitt S. et al. Relationship of patient age to pathologic features of the tumour and prognosis for patients with stage I or II breast cancer. J. Clin. Oncol. 1994; 12 (5): 888-94.Barber M.D., Jack W., Dixon J.M. Diagnostic delay in breast cancer. Br. J. Surg. 2004; 91 (1): 49-53.Lyubchenko L.N. Hereditary breast and/or ovarian cancer: DNA diagnostics, individual prognosis, treatment and prevention: Аuthor’s abstract.. M. D. М.; 2009 (in Russian). Любченко Л.Н. Наследственный рак молочной железы и/или яичников: ДНК-диагностика, индивидуальный прогноз, лечение и профилактика: Автореф. дис. д-ра мед. наук. М.; 2009.Breast Cancer Linkage Consortium (BCLC). Familial Cancer. 2003; 2 (3-4): 18-32.Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analisys of 22 studies. Am. J. Hum. Genet. 2003; 72 (5): 1117-30.Nathanson K.L., Wooster R., Weber B.L. Breast cancer genetics: what we know and what we need. Nature Med. 2001; 7 (5): 552-6.Lyubchenko L.N., Gar’kavceva R.F. DNA diagnostics and genetic counseling in breast cancer. In: Kushlinskiy N.E., Portnoy S.M., Loktionov K.P., ed. Breast cancer. М.: Russian Academy Of Medical Sciences, 2005: 198-209 (in Russian). Любченко Л.Н., Гарькавцева Р.Ф. ДНК-диагностика и медико-генетическое консультирование при наследственных формах рака молочной железы. В кн.: "Рак молочной железы. Под ред. Н.Е. Кушлинский, С.М. Портной, К.П. Локтионов. М.: РАМН; 2005: 198-209.Seynaeve C., Verhoog L.C., van de Bosch L.M., van Geel A.N., Menke-Pluymers M., Meijers-Heijboer E.J. et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur. J. Cancer. 2004; 40 (8): 1150-8.Metcalfe K., Lynch H.T., Ghadirian P., Tung N., Olivotto I., Warner E. et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 2004; 22 (12): 2328-35.Hajfty B.G., Harrold E., Khan A.J., Pathare P., Smith T.E., Turner B.C. et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002; 359 (9316): 1471-7.Pierce L.J., Levin A.M., Rebbeck T.R., Ben-David M.A., Friedman E., Solin L.J. et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J. Clin. Oncol. 2006; 24 (16): 2437-43.Foulkes W.D., Stefansson I.M., Chappuis P.O., Begin L.R., Goffin J.R., Wong N., Trudel M., Akslen L.A. Germline BRCA1 mutations and basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 2003; 95 (19): 1482-5.Eerola H., Heikkila P., Tamminen A., Aittomak K., Blomqvist C., Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation negative breast cancer families. Breast Cancer Res. 2005; 7: 93-100.Tilanus-Linthorst M.M., Obdeijn I.M., Hop W.C., Causer P.A., Leach M.O., Warner E. et al. A BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, UK, and Canadian MRI screening trials. Clin Cancer Res. 2007; 13 (24): 7357-62.Tilanus-Linthorst M.M., Kriege M., Boetes C., Hop W.C.J., Obdeijn I-M., Oosterwijk J.C. et al. Hereditary breast cancer growth rates and its impact on screening policy. Eur. J. of Cancer. 2005; 41 (11): 1610-17.Tilanus-Linthorst M.M., Obdeijn I.-M., Bartels K.C.M. MARIBS study. Lancet. 2005; 366 (9482): 291, 1434.Kriege M., Brekelmans C.T., Boetes C., Besnard P.E., Zonderland H.M., Obdeijn I.M. et al. Efficacy of breast cancer screening with MRI and mammography in women with a familial or genetic predisposition. N. Engl. J. Med. 2004; 351 (5): 427-37.Robson M.E., Offit K. Breast MRI for women with hereditary cancer risk. J. A. M. A. 2004; 292 (11): 1368-70.Foxcroft L.M., Evans E.B., Porter A.J. The diagnosis of breast cancer in women younger than 40. Breast. 2004; 13 (4): 297-306.Kaas R., Verhoef S., Wesseling J., Rookus M.A., Oldenburg H.S., Peeters M.J., Rutgers E.J. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers. Very low risk for subsequent breast cancer. Ann. Surg. 2010. 251 (3): 488-92.Hoogerbrugge N., Bult P., Widt-Levert L.M., Beex L.V., Kiemeney L.A., Ligtenberg M.J.L. et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J. Clin. Oncol. 2003; 21 (1): 41-5.Rebbeck T.R., Friebel T., Lynch H.T., Neuhausen S.L., van’t Veer L., Garber J.E. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol.- 2004; 22 (6). 1055-62.Stefanek M., Hartmann L., Nelson W. Risk-reduction mastectomy: clinical issues and research needs. J. Natl Cancer Inst. 2002; 94 (4). 307-8.Metcalfe K.A., Birenbaum-Carmeli D., Lubinski J., Gronwald J., Lynch H., Moller P. et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer. 2008; 122 (9): 2017-22.Daly M.B., Axilbund J.E., Buys S., Crawford B., Friedman S., Garber J.E. et al. Genetic/familial highrisk assessment clinical practice guidelines in oncology. The NCCN. 2002; version 1. http://www.nccn.orgFriedenbergR.M. The 21st century: the age of screening. Radiology. 2002; 223: 1.Duijm L.E.M., Groenewoud J.H., Hendriks J.H.C.L., de Koning H.J. Independent Double Reading of Screening Mammograms in the Netherlands: Effect of Arbitration Following Reader Disagreements. Radiology. 2004; 231 (2): 564.Gabe R., Duffy S.W. Evaluation of service screening mammography in practice: the impact on breast cancer mortality. Ann Oncol. 2005; 16: 153-62.Roder D., Houssami N., Farshid G., Gill G., Luke C., Downey P. et al. Population screening and intensity of screening are associated with reduced breast cancer mortality: evidence of efficacy of mammography screening in Australia. Breast Cancer Res. Treat. 2008; 108 (3): 409-16.Moss S.M., Cuckle H., Evans A., Johns L., Waller M., Bobrow L. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years’ follow-up: a randomised controlled trial. Lancet. 2006; 368 (9552): 2053-60.Scheuer L., Kauff N., Robson M., Kelly B., Barakat R., Satagopan J. et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J. Clin. Oncol. 2002; 20 (5): 1260-68.Komenaka I.K., Ditkoff B.A., Joseph K.A., Russo D., Gorroochurn P., Ward M. The development of interval breast malignancies in patients with BRCA mutations. Cancer. 2004; 100 (10): 2079-83.Houssami N., Cuzick J., Dixon J.M. The prevention, detection, and management of breast cancer. Med. J. Aust. 2006; 84 (5): 230-4.Vasen H.F., Tesfay E., Boonstra H., Mounts M.J., Rutgers E., Verheyen R. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur. J. Cancer. 2005. 41 (4): 549-54.Lehman C.D., White E., Peacock S., Drucker M.J., Urban N. Effect of age and breast density on screening mammograms with false-positive findings. Am. J. Roentgenol. 1999; 173 (6): 1651-5.Kolb T.M., Lichy J., Newhouse J.H. Occult cancer in women with dense breasts: detection with screening US diagnostic yield and tumor chracteristics. Radiology. 1998; 207 (1): 191-9.Hamilton L.J., Evans A.J., Wilson A.R., Scott N., Cornford E.J., Pinder S.E. et al. Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma. Clin Radiol. 2004; 59 (10): 895-902.Kaas R., Kroger R., Hendriks J.H., Besnard A.P., Koops W., Pameijer F.A. et al. The significance of circumscribed malignant mammographic masses in the surveillance of BRCA 1/2 gene mutation carriers. Eur. Radiol. 2004; 14: 1647-53.Veltman J. Mann R., Kok T., Obdeijn I.M., Hoogerbrugge N., Blickman J.G., Boetes C. Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI. Eur Radiol. 2008; 18 (5): 931-8.Wakeford R. The cancer epidemiology of radiation. Oncogene. 2004; 23 (38): 6404-28.Jansen-van der Weide M.C., Marcel J.W. Greuter L., Jansen L., Oosterwijk C., Pijnappel RM., Bock G. H. Exposure to low-dose radiation and the risk of breast cancer among women with a familial or genetic predisposition: a meta-analysis. Eur. Radiol. 2010; 20: 2547-56.Broeks A., Braaf L.M., Huseinovic A., Nooijen A., Urbanus J., Hogervorst F.B. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res. 2007; 9 (2): 106-114.Zubarev A.V., Gazhonova V.E., Hohlova E.A., Panfilova E.A., Churkina S.O., Luk’janova E.S. Elastography is a new method for various cancer localizations diagnose. J. Radiology-Practice. 2008; 6: 6-8 (in Russian). Зубарев А.В., Гажонова В.Е., Хохлова Е.А., Панфилова Е.А., Чуркина С.О., Лукьянова Е.С. Эластография - новый метод поиска рака различных локализаций. Радиология-практика. 2008; 6: 6-18.Thomas A., Fischer T., Frey H., Ohlinger R., Grunwald S., Blohmer J. Real-timeelastography - anadvanced method of ultrasound: firstresultsin108 patients with breast lesions. Ultrasound Obstetr. Gynecol. 2006; 28 (3): 335-40.Zhi H., Ou B., Luo B., Feng X., Wen Y., Yang H. Comparison of ultrasound elastography, mammography, and sonography in the diagnosis of solid breast lesions. J. Ultrasound. Med. 2007; 26: 807-15.Hill K., Bjember Dzh., ter Haar G. Physical Principles of Medical Ultrasonics. M.: Fizmatlit, 2008 (in Russian). (Хилл К., Бэмбер Дж., тер Хаар Г. Ультразвук в медицине. Физические основы применения. 2-е изд. М.: Физматлит; 2008.)Tardivon A., Khoury C. E., Thibault F., Wyler A. Elastography of the breast: Prospective study of 122 lesions. Radiology. 2007; 88. 657-62.Kuhl C.K., Schrading S., Leutner C.C., Morakkabati-Spitz N., Wardelmann E., Fimmers R. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J. Clin. Oncol.- 2005; 23 (33): 8469-76.Warner E., Plewes D.B., Hill K.A., Causer P.A., Zubovits J.T., Jong R.A., Cutrara M. R. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. J. A. M. A. 2004; 292 (11): 1317-25.Kolb T.M., Lichy J. Newhouse J.H. Comparison of the performance of screening mammography, physical examination, and breast ultrasound and evaluation of factors that influence them: An analysis of 27,825 patient evaluations. Radiology. 2002; 225 (1): 165-75.Crystal P., Strano S.D., Shcharynski S., Koretz M.J. Using sonography to screen women with mammographically dense breasts. Am. J. Roentgenol. 2003; 181 (1): 177-82.Sim L.S., Hendriks J.H., Fook-Chong S.M. Breast ultrasound in women with familial risk of breast cancer. Ann. Acad. Med. Singapore. 2004; 33(23): 600-6.Hofman M.B. MRI principles in MR mammography. In: Erasmus course on magnetic resonance imaging. MR of the breast. VU medisch centrum, 2004: 4-8.Berg W.A., Gutierrez L., NessAiver M.S., Carter W.B., Bhargavan M., Lewis R.S., Ioffe O.B. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004; 233 (3): 830-49.Bedrosian I., Mick R., Orel S.G., Schnall M., Reynolds C., Spitz F.R. et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer. 2003; 98 (3): 468-73.Liberman L., Morris E.A., Dershaw D.D., Abramson A.F., Tan L.K. MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer. Am. J. Rorntgenol. 2003; 180: 901-10.Schelfout K., Van Goethem M., Kersschot E., Colpaert C., Schelfhout A.M., Leyman P. et al. Contrast-enhanced MR imaging of breast lesions and effect on treatment. Eur. J. Surg. Oncol. 2004; 30 (5): 501-7.Lehman C.D., Blume J.D., Thickman D., Bluemke D.A., Pisano E., Kuhl C. et al. Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial. J. Surg. Oncol. 2005;.92 (1): 9-15.Lee S.G., Orel S.G., Woo I.J., Cruz-Jove E., Putt M.E., Solin L.J. et al. MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology. 2003. 226 (3): 773-8.Pediconi F., Venditti F., Padula S., Roselli A., Moriconi E., Giacomelli L. et al. CE-magnetic resonance mammography for the evaluation of the contralateral breast in patients with diagnosed breast cancer. Radiol. Med. 2005; 110 (1-2): 61-8.Lehman C.D., Blume J.D., Weatherall P., Thickman D. Hylton N., Warner E. et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. et al. Cancer. 2005; 103 (9): 1898-905.Lehman C.D., Isaacs C. Schnall M.D. Cancer yield of mammography, MRI, and ultrasound in high risk women: prospective multi-institution breast cancer screening study. Radiology. 2007; 244: 381-8.Leach M.O., Boggis C.R., Dixon A.K., Easton D.F., Eeles R.A., Evans D.G. et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005; 365: 1769-78.Sardanelli F., Podo F., D’Agnolo G., Verdecchia A., Santaquilani M., Musumeci R. et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology. 2007; 242 (3): 698-715.Trufanov G.E., Serebrjakova S.V., Juhno E.A. Breast MRI. St. Petersburg: JeLBI-SPb, 2009 (in Russian). Труфанов Г.Е., Серебрякова С.В., Юхно Е.А. МРТ в маммологии. СПб.: ЭЛБИСПб; 2009.Fisher U., Baum F., Ljuftner-Nagel’ S. Direct Diagnosis in Radiology: Breast Imaging. M.: MEDpress-inform, 2009 (in Russian). Фишер У., Баум Ф., Люфтнер-Нагель С. Лучевая диагностика. Заболевания молочных желез. M.: МЕДпрессинформ: 2009.Davis P.L., McCarty K.S. Jr. Sensitivity of enhanced MRI for detection of breast cancer: new, multicentric, residual, and recurrent. Eur. Radiol. 1997; 7: 289-98.Orel S.G., Schnall M.D. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology. 2001; 220: 13-30.Heywang-Kobrunner S.H., Viehweg P., Heinig A., Kuchler C. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur. J. Radiol. 1997; 24: 94-108.Hagen A.I., Kvistad K.A., Maehle L., Holmen M.M., Aase H., Styr B. et al. Sensitivity of MRI versus conventional screening in the diagnosis of BRCAassociated breast cancer in a national prospective series. Breast. 2007; 16 (4): 367-74.Riedl C.C., Ponhold L., Flory D., Weber M., Kroiss R., Wagner T. et al. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin. Cancer. Res. 2007; 15 (13): 6144-52.Samphao S., Wheeler A.J., Rafferty E., Michaelson J.S., Specht M.C., Gadd M.A. et al. Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging. Am. J. Surg. 2009; 198 (4): 538-43.Sardanelli F., Podo F. Breast imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur. Radiol. 2007; 17: 873-87.Warner E., Messersmith H., Causer P., Eisen A., Shumak R., Plewes D. Systematic review: Using magnetic resonance imaging to screen women at high risk for breast cancer. Ann. Intern. Med. 2008; 148 (9): 671-9.Morrow M. The certainties and the uncertainties of ductal carcinoma in situ. J. Natl Cancer Inst. 2004; 96: 424-5.Baxter N.N., Virnig B.A., Durham S.B., Tuttle T.M. Trends in the treatment of ductal carcinoma in situ of the breast. J. Natl Cancer Inst. 2004; 96: 443-8.Ernster V.L., Ballard-Barbash R., Barlow W.E., Zheng Y., Weaver D.L., Cutter G. et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002; 94 (20): 1546-54.Jansen S.A., Paunesku T., Fan X., Woloschak G.E., Vogt S., Conzen S.D. et al. Ductal carcinoma in situ: x-ray fluorescence microscopy and dynamic contrast MR-imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model. Radiology. 2009; 253 (2): 399-406.Morakkabati-Spitz N., Leutner C., Schild H., Traeber F., Kuhl C. Diagnostic usefulness of segmental and linear enhancement in dynamic breast MRI. Eur. Radiol. 2005; 15: 2010-17.Teifke A., Hlawatsch A., Beier T., Werner Vomweg T., Schadmand S., Schmidt M. et al. Undetected malignancies of the breast: dynamic contrast-enhanced MR imaging at 1.0 T. Radiology. 2002; 224 (3): 881-8.Morris E.A., Liberman L., Ballon D.J., Robson M., Abramson A.F., Heerdt A., Dershaw D.D. MRI of occult breast carcinoma in a high-risk population. Am. J. Roentgenol. 2003; 181 (3): 619-26.Kuhl C.K., Schrading S., Bieling H.B., Wardelmann E., Leutner C.C., Koenig R. et al. MRI for diagnosis of pure ductal carcinoma in situ: A prospective observational study. Lancet. 2007; 370 (9586): 485-92.Menell J.H., Morris E.A., Dershaw D.D., Abramson A.F., Brogi E., Liberman L. Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J. 2005; 11 (6): 382-90.Warner E., Hill K., Causer P., Plewes D., Jong R., Yaffe M. et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J. Clin. Oncol. 2011; 29 (13): 1664-9.Lagios M.D., Margolin F.R., Westdahl P.R., Rose M.R. et al. Mammographically detected duct carcinoma in situ: Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer (Philad.). 1989; 63 (4): 618-24.Silverstein M.J., Poller D.N., Waisman J.R., Colburn W.J., Barth A., Gierson E.D. et al. Prognostic classification of breast duct carcinoma in situ. Lancet. 1995; 345: 1154-7.Schrading S., Kuhl C.K. Mammographic, US, and MR imaging phenotypes of familial breast cancer. Radiology. 2008; 246 (1): 58-70.Brown L.F., Guidi A.J., Schnitt S.J., Van De Water L., Iruela-Arispe M.L., Yeo T.K. et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin. Cancer Res. 1999; 5 (5): 1041-56.Cao Y., Paner G.P., Kahn L.B., Rajan P.B. Noninvasive carcinoma of the breast: angiogenesis and cell proliferation. Arch. Pathol. Lab. Med. 2004; 128 (8): 893-6.Dershaw D.D., Abramson A., Kinne D.W. Ductal carcinoma in situ: mammographic findings and clinical implications. Radiology. 1989; 170 (2): 411-5.Menell J.H., Morris E.A., Dershaw D.D., Abramson A.F., Brogi E., Liberman L. Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J. 2005; 11 (6); 382-90.Tilanus-Linthorst M., Verhoog L., Obdeijn I.M., Bartels K., Menke-Pluymers M., Eggermont A. et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int. J. Cancer. 2002; 102 (1): 91-5.Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancer in carriers of BRCA1 or BRCA2 mutations and sporadic cases / No authors listed. Lancet. 1997; 349 (9064): 1505-10.Hwang E.S., McLennan J.L., Moore D.H., Crawford B.B., Esserman L.J., Ziegler J.L. Ductal carcinoma in situ in BRCA mutation carriers. J. Clin. Oncol. 2007; 25 (6): 642-7.Warner E., Causer P.A., Wong J.W., Wright F.C., Jong R.A., Hill K.A. et al. Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study. Breast J. 2011; 17 (1): 9-17.Lin S.P., Brown J.J. MR contrast agents: physical and pharmacologic basics. J. Magn. Reson. Imaging. 2007; 25 (5): 884-9.Griebsch I., Brown J., Boggis C., Dixon A., Dixon M., Easton D. et al. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br. J. Cance. 2006; 95 (7): 801-10.Schmutzler R.K., Rhiem K., Breuer P., Wardelmann E., Lehnert M., Coburger S., Wappenschmidt B. Outcome of a structured surveillance programme in women with a familial predisposition of breast cancer. Eur. J. Cancer Prev. 2006; 15 (6): 483-9.